Zai Lab Stock Forecast, Price & News

Zai Lab (NASDAQ:ZLAB) Frequently Asked Questions

Is Zai Lab a buy right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Zai Lab in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Zai Lab stock.
View analyst ratings for Zai Lab or view top-rated stocks.

How has Zai Lab's stock been impacted by Coronavirus (COVID-19)?

Zai Lab's stock was trading at $50.13 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ZLAB shares have increased by 4.1% and is now trading at $52.20.
View which stocks have been most impacted by COVID-19.

When is Zai Lab's next earnings date?

Zai Lab is scheduled to release its next quarterly earnings announcement on Monday, March 7th 2022.
View our earnings forecast for Zai Lab.

How were Zai Lab's earnings last quarter?

Zai Lab Limited (NASDAQ:ZLAB) released its quarterly earnings results on Tuesday, November, 9th. The company reported ($1.01) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($1.24) by $0.23. The company had revenue of $43.10 million for the quarter, compared to analyst estimates of $42.43 million.
View Zai Lab's earnings history.

What guidance has Zai Lab issued on next quarter's earnings?

Zai Lab issued an update on its third quarter earnings guidance on Tuesday, November, 9th. The company provided earnings per share guidance of ($1.01) for the period, compared to the Thomson Reuters consensus EPS estimate of ($1.27). The company issued revenue guidance of $43.10 million, compared to the consensus revenue estimate of $43.78 million.

What price target have analysts set for ZLAB?

6 equities research analysts have issued 1-year target prices for Zai Lab's shares. Their forecasts range from $136.00 to $250.00. On average, they anticipate Zai Lab's stock price to reach $207.87 in the next year. This suggests a possible upside of 298.2% from the stock's current price.
View analysts' price targets for Zai Lab or view top-rated stocks among Wall Street analysts.

Who are Zai Lab's key executives?

Zai Lab's management team includes the following people:

• Ying Du, Chairman & Chief Executive Officer (LinkedIn Profile)
• Tao Fu, President, Chief Operating Officer & Director (LinkedIn Profile)
• Billy Cho, Chief Financial Officer
• Ning Xu, Executive VP & Head-Clinical Operations
• James Yan, Chief Operating Officer-Research & Development

Who are some of Zai Lab's key competitors?

Some companies that are related to Zai Lab include Horizon Therapeutics Public (HZNP), Viatris (VTRS), Catalent (CTLT), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Elanco Animal Health (ELAN), Ono Pharmaceutical (OPHLF), Dr. Reddy's Laboratories (RDY), Teva Pharmaceutical Industries (TEVA), United Therapeutics (UTHR), Bausch Health Companies (BHC), Jazz Pharmaceuticals (JAZZ), Grifols (GRFS), Organon & Co. (OGN) and Biohaven Pharmaceutical (BHVN).
View all of ZLAB's competitors.

What other stocks do shareholders of Zai Lab own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zai Lab investors own include NVIDIA (NVDA), CRISPR Therapeutics (CRSP), Inseego (INSG), Niu Technologies (NIU), JD.com (JD), Bilibili (BILI), Marvell Technology (MRVL), Baidu (BIDU), BioXcel Therapeutics (BTAI) and Baozun (BZUN).

When did Zai Lab IPO?

(ZLAB) raised $100 million in an IPO on Wednesday, September 20th 2017. The company issued 5,900,000 shares at $16.00-$18.00 per share. J.P. Morgan, Citigroup and Leerink Partners acted as the underwriters for the IPO.

What is Zai Lab's stock symbol?

Zai Lab trades on the NASDAQ under the ticker symbol "ZLAB."

Who are Zai Lab's major shareholders?

Zai Lab's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Baillie Gifford & Co. (5.33%), M&G Investment Management Ltd. (0.21%), Crossmark Global Holdings Inc. (0.00%) and Parallel Advisors LLC (0.00%). Company insiders that own Zai Lab stock include Harald Reinhart, John D Diekman, John D Diekman, Kai-Xian Chen, Peter Wirth, Tao Fu, William Ki Chul Cho and Ying Du.
View institutional ownership trends for Zai Lab.

Which institutional investors are buying Zai Lab stock?

ZLAB stock was bought by a variety of institutional investors in the last quarter, including Baillie Gifford & Co., M&G Investment Management Ltd., Crossmark Global Holdings Inc., and Parallel Advisors LLC.
View insider buying and selling activity for Zai Lab or or view top insider-buying stocks.

How do I buy shares of Zai Lab?

Shares of ZLAB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Zai Lab's stock price today?

One share of ZLAB stock can currently be purchased for approximately $52.20.

How much money does Zai Lab make?

Zai Lab has a market capitalization of $5.03 billion and generates $48.96 million in revenue each year.

How many employees does Zai Lab have?

Zai Lab employs 1,194 workers across the globe.

What is Zai Lab's official website?

The official website for Zai Lab is www.zailaboratory.com.

Where are Zai Lab's headquarters?

Zai Lab is headquartered at 4560 JINKE ROAD BLDG. 1 FOURTH FLOOR PUDONG, SHANGHAI F4, 201210.

How can I contact Zai Lab?

Zai Lab's mailing address is 4560 JINKE ROAD BLDG. 1 FOURTH FLOOR PUDONG, SHANGHAI F4, 201210. The company can be reached via phone at 862161632588, via email at [email protected], or via fax at 86-21-6163-2570.